The Project star Meshel Laurie reveals whopping 60kg weight loss as she pleads for government to add Ozempic to PBS
The Project panellist, 51, has been open about her extreme physical transformation after undergoing gastric bypass surgery in 2016, which resulted in the TV host looking completely unrecognisable.
Meshel appeared on the Kyle and Jackie O show on Tuesday, where she admitted to having recently taken weight loss medication Mounjaro and credited the drug with helping her lower the scale.
She called on the Albanese government to add the GLP-1 injectable drug, similar to Ozempic, to the PBS to subsidise the cost and make it more affordable for Australians, describing the effects as "amazing" and "life-changing".
"I have to make a plea to the government to add this medication to the PBS, please, because it costs over $600 a month," she said.
"For a lot of people, it's prohibitive."
"If obesity costs Australia about $12 billion a year, then surely, we can afford to make this medication more affordable."
Mounjaro was initially used for treating type 2 diabetes until it gained popularity for its weight loss effects in recent years.
The Therapeutic Goods Administration (TGA) in 2024 expanded the drug's usage to encompass obese or overweight Australians with weight-related health issues like high blood pressure, heart disease or sleep apnoea.
Speaking about the reported side effects, including stomach pains, Mishel said she hasn't experienced any.
She said even if she had, it would be "worth it" to continue achieving a physical transformation while bypassing any "exercise" in the process.
"As I said, I did everything else before. So, I lost a bit of weight, I lost about 30kg.
"And then about a year ago, I started using Mounjaro.
"And that has not only knocked off the next 30-40kgs, but it has absolutely dealt with the problem. Like, I don't think about food anymore."
Elsewhere in the wide-ranging interview, Meshel opened up about the personal heartbreak that spurred her to lose weight in the first place.
'My dad died of Type 2 Diabetes (in) 2019,' she said.
'But for the five years before that he lived with the kids and I.
'I was watching (him suffer) in real time, out the kitchen window, because he was in a granny flat. I didn't put him in the driveway; he had a flat.'
The media personality was a regular on Ten's The Project from 2014 to 2018, after which she was sacked while on leave for her father's health.
Meshel said she was ready to go back to work after 12 weeks, only to be told all the "spots were filled for the next couple of months"
'In fact, I was never notified that I was being let go," she said on Instagram.
Meshel subsequently carved out a career as an author and published her bestselling novel, Buddhism for the Unbelievably Busy, in 2017, followed by CSI Told You Lies: Giving Victims a Voice Through Forensics in 2021.
In Buddhism for the Unbelievably Busy, Meshel declared she was "embarrassed" about having had surgery to lose weight.
"Yes, it's embarrassing to have to go to that length to rein my body in, but I'd rather be embarrassed than unable to walk," she wrote.
"In a way, I feel lucky to have had such clear signals from my body that I needed to turn my health burner back on, when I still had time to do something about it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
5 hours ago
- West Australian
World-first study could provide MS breakthrough
A world-first study aims to identify a person's genetic risk of developing multiple sclerosis by using their DNA. The research will investigate why some people develop MS and others don't, even if they are exposed to the same common virus. University of South Australia's David Stacey told AAP the pilot study would involve an innovative approach, called "recall by genotype", which has never been used in MS research. "It's like studying the immune system's blueprint before the disease starts," said Dr Stacey, who leads the study. As the most common acquired chronic neurological disease affecting young adults, MS impacts more than 33,000 Australians. Symptoms can include loss of motor function, loss of sensation, pain, vision changes and changes to thinking and memory. While there is no cure or single known cause for MS, many genetic and environmental factors are believed to contribute to its development. Dr Stacey says the study will select two groups of participants based on whether they have a high or low genetic risk of MS. By comparing the groups, researchers hope to understand how their immune systems respond to the Epstein-Barr virus, a disease that causes glandular fever and has been strongly linked to MS. While most people get infected with Epstein-Barr virus, only a small number develop MS. Researchers believe differences in how a person's immune system reacts to the virus might explain why some people get MS and others don't. "It could also help identify early biological markers that show when MS might be starting to develop. This may lead to earlier detection, new treatments or even prevention," Dr Stacey said. "We want to take learnings from this to help inform a larger, more scaled-up version of this study." The research is funded through MS Australia's latest Incubator Grant round, which supports ideas aimed at opening new directions in MS research. "Our mission is to accelerate research and improve outcomes for every person living with MS," chief executive Rohan Greenland said.
Perth Now
5 hours ago
- Perth Now
World-first study could provide MS breakthrough
A world-first study aims to identify a person's genetic risk of developing multiple sclerosis by using their DNA. The research will investigate why some people develop MS and others don't, even if they are exposed to the same common virus. University of South Australia's David Stacey told AAP the pilot study would involve an innovative approach, called "recall by genotype", which has never been used in MS research. "It's like studying the immune system's blueprint before the disease starts," said Dr Stacey, who leads the study. As the most common acquired chronic neurological disease affecting young adults, MS impacts more than 33,000 Australians. Symptoms can include loss of motor function, loss of sensation, pain, vision changes and changes to thinking and memory. While there is no cure or single known cause for MS, many genetic and environmental factors are believed to contribute to its development. Dr Stacey says the study will select two groups of participants based on whether they have a high or low genetic risk of MS. By comparing the groups, researchers hope to understand how their immune systems respond to the Epstein-Barr virus, a disease that causes glandular fever and has been strongly linked to MS. While most people get infected with Epstein-Barr virus, only a small number develop MS. Researchers believe differences in how a person's immune system reacts to the virus might explain why some people get MS and others don't. "It could also help identify early biological markers that show when MS might be starting to develop. This may lead to earlier detection, new treatments or even prevention," Dr Stacey said. "We want to take learnings from this to help inform a larger, more scaled-up version of this study." The research is funded through MS Australia's latest Incubator Grant round, which supports ideas aimed at opening new directions in MS research. "Our mission is to accelerate research and improve outcomes for every person living with MS," chief executive Rohan Greenland said.
The Australian
7 hours ago
- The Australian
Albanese government praises ‘critical' program in teen vape fight
The Albanese government is celebrating after a key study found an anti-vaping program is helping curb the spike in fuming teens. A randomised controlled trial involving some 5000 students from 40 schools found participants were 65 per cent less likely to vape after 12 months when compared to students who did not take part in the program. The findings were published on Tuesday in the world leading health journal, The Lancet. Health Minister Mark Butler praised the results, calling the program 'a critical part of our vaping strategy'. Health Minister Mark Butler has praised the results of a clinical trial that found. Picture: Martin Ollman / NewsWire 'Vaping rates exploded, especially in the last five years, literally exploded year on year,' Mr Butler told reporters at Parliament House, flanked by students. 'This was sold to countries around the world as a therapeutic good that would allow hardened smokers, usually in middle age, to kick the habit if other attempts to kick smoking had not worked. 'But what we found relatively quickly was this was quite a different strategy by big tobacco. 'It was a strategy to recruit a new generation to nicotine addiction.' He said he was 'delighted we have been able to fund' the program, run by the Our Futures Institute. Under the program, students learn about the harms of vaping through visual stories and game-like activities, such as quizzes. Health Minister Mark Butler says 'big tobacco' was trying to lure in Australian teenagers. Picture: Martin Ollman / NewsWire In 2019, 9.6 per cent of teens aged 14-17 were estimated to have used vapes, according to official data. It nearly tripled to 28 per cent by 2023. Earlier this year, the Albanese government said numbers the numbers were falling after a series of measures aimed at curbing the uptake among young Australians. Among the measures were banning single-use vapes. According data put out in January, vaping rates for Australian 15 and had fallen more than a third since 2023. The data also showed the number of 'never-vapers' among 14-17-year-olds had reached a record high of 85 per cent.
